Cat. No.: HY-108463

A-967079

16 Cited Publications

Avis client

Based on 16 publication(s) in Google Scholar

A-967079 is a selective TRPA1 receptor antagonist with IC₅₀s of 67 nM and 289 nM at human and rat TRPA1 receptors, respectively, and has good penetration into the blood-brain barrier.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.30%
CAS No.: 1170613-55-4
Formule: C₁₂H₁₄FNO
Masse moléculaire:207.24

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

A-967079 Chemical Structure

CAS No.: 1170613-55-4

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vivo
- Essai clinique
Chemical Information
Publications (16)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

A-967079 is a selective TRPA1 receptor antagonist with IC₅₀s of 67 nM and 289 nM at human and rat TRPA1 receptors, respectively, and has good penetration into the blood-brain barrier^[1].

IC₅₀ & Target

IC50: 67 nM (human TRPA1 receptor), 289 nM (rat TRPA1 receptor)^[1]

Voir tous les produits spécifiques à Isoform TRP Channel :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	79 nM Compound: A967079	Antagonist activity at human TRPA1 expressed in HEK293 cells assessed as inhibition of CA-induced increase in calcium influx incubated for 10 mins prior to CA addition by Fluo-4-AM dye based fluorescence assayy Antagonist activity at human TRPA1 expressed in HEK293 cells assessed as inhibition of CA-induced increase in calcium influx incubated for 10 mins prior to CA addition by Fluo-4-AM dye based fluorescence assayy	[PMID: 30878828]

In Vivo

Systemic injection of A-967079 (30 μmol/kg, i.v.) decreases the responses of wide dynamic range (WDR), and nociceptive specific (NS) neurons following noxious pinch stimulation of the ipsilateral hind paw in uninjured and CFA-inflamed rats. Similar to its actions in uninjured rats, administration of A-967079 (30 μmol/kg, i.v.) to complete Freund's adjuvant (CFA)-inflamed rats significantly reduces WDR neuronal responses to noxious pinch stimulation compared to baseline firing (p=0.0013, repeated-measures ANOVA) and the vehicle group (p=0.0001, two-way ANOVA). The maximum observed effect (61.1±10.97% decrease from baseline levels) on pinch-evoked activity in inflamed rats occur 35 min after injection. In contrast to uninjured rats, injection of A-967079 to CFA-inflamed rats also significantly (p=0.0004, and p=0.0001 for the repeated-measures and two-way ANOVA's, respectively) reduces responses of WDR neurons to 10-g von Frey hair stimulation. The maximal observed decrease in von Frey-evoked activity is 67.69±18.39% from baseline levels (35 min post-injection), and is thus comparable to the effects of A-967079 on pinch-evoked activity in inflamed rats^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1170613-55-4
Appearance Solid
Masse moléculaire 207.24
Formule C₁₂H₁₄FNO
Color White to off-white
SMILES

CCC(/C(C)=C/C1=CC=C(F)C=C1)=N\O
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (16)

All Bio/Physico-chemical AssayWBIn Vivo Efficacy StudyCell Imaging/StainingMicrobiological AssayIF

Sort by:

Journal Impact Factor

Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Cancer Lett

RACK1 promotes the invasive activities and lymph node metastasis of cervical cancer via galectin-1. [Abstract]

2020 Jan 28;469:287-300. PMID: 31705928
Cell Rep

Mechanosensitive calcium channels and integrins coordinate the reprogramming of colorectal cancer cells into a fetal-like state. [Abstract]

2025 Sep 22;44(10):116308. PMID: 40986425
Br J Pharmacol

TRPA1 up-regulation mediates oxidative stress in a pulpitis model in vitro. [Abstract]

2024 May 14. PMID: 38744683

A-967079 purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2024 May 14. [Abstract]

Effect of A 967079 (1 μM), another structurally unrelated TRPA1 channel antagonist on the peak amplitude of Ca²⁺ traces evoked by AITC (30 μM) in control and inflammatory conditions, as indicated in the figure.

A-967079 purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2024 May 14. [Abstract]

Effect of poly(I:C), and TRPA1 channel agonists and antagonists on mitochondrial superoxide production in 60 min. The following treatments were applied, as indicated in the figure: 100 μM AITC (AITC), 300 μM cinnamaldehyde (CA), 10 μM HC-030031 (HC), and 1 μM A 967079 (A96) in the presence or absence of poly(I:C).
Commun Biol

Molecular defense strategy of volatile organic compound-emitting plants (order Piperales) against herbivorous mammals. [Abstract]

2025 Dec 1;9(1):19. PMID: 41326785

A-967079 purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 Dec 1;9(1):19. [Abstract]

Whole-cell TRPA1 currents elicited by the application of 1 mM 4-A and 500 μM SH. This response was blocked by 10 μM A-967079 (A-96), a selective TRPA1 inhibitor.
ACS Omega

Identification of Phialomustin‑B (PHL-B) as a Novel Natural TRPA1 Channel Inhibitor. [Abstract]

2025 Aug 21;10(34):39192-39202. PMID: 40918390
Cancers (Basel)

TRPA1 Contributes to FGFR2c Signaling and to Its Oncogenic Outcomes in Pancreatic Ductal Adenocarcinoma-Derived Cell Lines. [Abstract]

2024 Jan 31;16(3):609. PMID: 38339360

A-967079 purchased from MedChemExpress. Usage Cited in: Cancers (Basel). 2024 Jan 31;16(3):609. [Abstract]

PANC-1 and MIA PaCa-2 cells were pre-treated with the selective TRPA1 pore function inhibitor (A-967079) for 1 h and then left untreated or stimulated with FGF2 for 24 h. Western blot analysis showed that the inhibition of the TRPA1 pore function did not impact PANC-1 cell response to FGF2 in terms of E-cadherin/vimentin modulation toward EMT enhancement.
Mol Cell Biochem

Transient receptor potential ankyrin 1 contributes to the ATP-elicited oxidative stress and inflammation in THP-1-derived macrophage. [Abstract]

2020 Oct;473(1-2):179-192. PMID: 32627113
ACS Infect Dis

Discovery of A-967079 as an Enterovirus D68 Antiviral by Targeting the Viral 2C Protein. [Abstract]

2024 Dec 13;10(12):4327-4336. PMID: 39578369

A-967079 purchased from MedChemExpress. Usage Cited in: ACS Infect Dis. 2024 Dec 13;10(12):4327-4336. [Abstract]

Chemical structure of A-967079 and the plaque assay images of A-967079 (0-10 μM) against EV-D68 US/MO/14-18947 in RD cells. The plaques were quantified using Image J. Images were representatives of two independent replicates.

A-967079 purchased from MedChemExpress. Usage Cited in: ACS Infect Dis. 2024 Dec 13;10(12):4327-4336. [Abstract]

Broad-spectrum antiviral activity of A-967079 in RD cells.

A-967079 purchased from MedChemExpress. Usage Cited in: ACS Infect Dis. 2024 Dec 13;10(12):4327-4336. [Abstract]

Plaque assay images of A-967079 (0-3 μM) against EV-D68 US/MO/14-18947 in A549 cells. The plaques were quantified using Image J. Images were representatives of two independent replicates.

A-967079 purchased from MedChemExpress. Usage Cited in: ACS Infect Dis. 2024 Dec 13;10(12):4327-4336. [Abstract]

A-967079 (0-3 μM) inhibited EV-D68 VP1 synthesis in immunofluorescence assay. RD cells were infected by EV-D68 US/MO/14-18947 at a MOI of 1. Cells were fixed 9 hours postinfection. Cells were stained with anti-VP1 and Hoechst to detect EV-D68 VP1 and nucleus. The images were representatives of three independent experiments.
Front Mol Neurosci

Oxaliplatin Depolarizes the IB4- Dorsal Root Ganglion Neurons to Drive the Development of Neuropathic Pain Through TRPM8 in Mice. [Abstract]

2021 Jun 4;14:690858. PMID: 34149356
Pest Manag Sci

A novel negative thermotaxis behavior in rice planthoppers is regulated by TRPA1 channel. [Abstract]

2020 Sep;76(9):3003-3011. PMID: 32248592
Cell Stress Chaperones

Transient receptor potential ankyrin 1 contributes to the lysophosphatidylcholine-induced oxidative stress and cytotoxicity in OLN-93 oligodendrocyte. [Abstract]

2020 Nov;25(6):955-968. PMID: 32572784
Headache

TRPM3 activation causes CGRP release in trigeminal neurons: Implications for migraine mechanisms. [Abstract]

2025 Oct 24. PMID: 41133435

A-967079 purchased from MedChemExpress. Usage Cited in: Headache. 2025 Oct 24. [Abstract]

CGRP levels were measured in male and female dura mater following baseline collection and stimulation with the TRPA1 antagonist A-967079 (3 µM), TRPM3 agonist CIM0216 (100 µM), or their combination. In both sexes, CIM0216 increased CGRP release compared to baseline and vehicle.

A-967079 purchased from MedChemExpress. Usage Cited in: Headache. 2025 Oct 24. [Abstract]

CGRP levels in male dura mater and male TG were measured at baseline and after stimulation with the TRPA1 antagonist A-967079 (3 µM), the TRPA1 agonist supercinnamaldehyde (100 µM), or their combination. Supercinnamaldehyde increased CGRP release in both dura mater and TG. This effect was reduced when tissues were pretreated with A-967079.
Pain Res Manag

Exploring the Analgesic Initiation Mechanism of Tuina in the Dorsal Root Ganglion of Minor CCI Rats via the TRPV1/TRPA1-cGMP Pathway. [Abstract]

2024 Jul 24:2024:2437396. PMID: 39104725
Pediatr Blood Cancer

Evaluation of TRPA1 as a Therapeutic Target in MYCN-Amplified Neuroblastoma. [Abstract]

2025 Sep;72(9):e31875. PMID: 40556352
bioRxiv

2023 Jul 2.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (482.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.8253 mL

24.1266 mL

48.2532 mL

5 mM

0.9651 mL

4.8253 mL

9.6506 mL

10 mM

0.4825 mL

2.4127 mL

4.8253 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (12.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (12.06 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Animal Administration^[1]

Rats^[1]
Male Sprague-Dawley rats (250-400 g) are used for all experiments and are housed in a temperature controlled room with a 12/12-hr day/night cycle. Food and water are available ad libitum. Spontaneous and evoked neuronal activity is then measured 5, 15, 25, and 35 min after systemic injection of A-967079 (30 μmol/kg, i.v.) or vehicle (polyethylene glycol). The intravenous injection of A-967079 or vehicle is completed over a 6-7 min period. The i.v. dose of A-967079 is selected based on extrapolated plasma levels that are effective in behavioral studies^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (273 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. McGaraughty S, et al. TRPA1 modulation of spontaneous and mechanically evoked firing of spinal neurons in uninjured, osteoarthritic, and inflamed rats. Mol Pain. 2010 Mar 5;6:14. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.8253 mL	24.1266 mL	48.2532 mL	120.6331 mL
	5 mM	0.9651 mL	4.8253 mL	9.6506 mL	24.1266 mL
	10 mM	0.4825 mL	2.4127 mL	4.8253 mL	12.0633 mL
	15 mM	0.3217 mL	1.6084 mL	3.2169 mL	8.0422 mL
	20 mM	0.2413 mL	1.2063 mL	2.4127 mL	6.0317 mL
	25 mM	0.1930 mL	0.9651 mL	1.9301 mL	4.8253 mL
	30 mM	0.1608 mL	0.8042 mL	1.6084 mL	4.0211 mL
	40 mM	0.1206 mL	0.6032 mL	1.2063 mL	3.0158 mL
	50 mM	0.0965 mL	0.4825 mL	0.9651 mL	2.4127 mL
	60 mM	0.0804 mL	0.4021 mL	0.8042 mL	2.0106 mL
	80 mM	0.0603 mL	0.3016 mL	0.6032 mL	1.5079 mL
	100 mM	0.0483 mL	0.2413 mL	0.4825 mL	1.2063 mL

Keywords

A-967079

16 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

A-967079

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

Clinical Compound Library

CNS-Penetrant Compound Library

Chemical Probe Library

Mechanoreceptors Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Ion Channel Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) A-967079

Voir tous les produits spécifiques à Isoform TRP Channel

Activité biologique

Chemical Information

Publications (16)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

A-967079

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

Clinical Compound Library

CNS-Penetrant Compound Library

Chemical Probe Library

Mechanoreceptors Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Ion Channel Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) A-967079

Voir tous les produits spécifiques à Isoform TRP Channel

Activité biologique

Chemical Information

Publications (16)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

A-967079 Related Classifications

HY-108463 Related Classifications